Zebrafish: An in Vivo Model for the Study of Neurological Diseases

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2008 Oct 3

PMID 18830398

Citations 54

Authors

J D Best

Wendy K Alderton

Affiliations

Soon will be listed here.

Abstract

As the population ages, there is a growing need for effective therapies for the treatment of neurological diseases. A limited number of therapeutics are currently available to improve cognitive function and research is limited by the need for in vivo models. Zebrafish have recently become a focus of neurobehavioral studies since larvae display neuropathological and behavioral phenotypes that are quantifiable and relate to those seen in man. Due to the small size of Zebrafish larvae, assays can be undertaken in 96 well plates and as the larvae can live in as little as 200 mul of fluid, only a few milligrams of compound are needed for screening. Thus in vivo analysis of the effects of compounds can be undertaken at much earlier stages in the drug discovery process. This review will look at the utility of the zebrafish in the study of neurological diseases and its role in improving the throughput of candidate compounds in in vivo screens.

Citing Articles

Comparing Prion Proteins Across Species: Is Zebrafish a Useful Model?.

Burato A, Legname G Mol Neurobiol. 2024; 62(1):832-845.

PMID: 38918277 PMC: 11711791. DOI: 10.1007/s12035-024-04324-z.

Inhibitory control in teleost fish: a methodological and conceptual review.

Lucon-Xiccato T Anim Cogn. 2024; 27(1):27.

PMID: 38530456 PMC: 10965611. DOI: 10.1007/s10071-024-01867-5.

Assessing Drug Administration Techniques in Zebrafish Models of Neurological Disease.

Chaoul V, Dib E, Bedran J, Khoury C, Shmoury O, Harb F Int J Mol Sci. 2023; 24(19).

PMID: 37834345 PMC: 10573323. DOI: 10.3390/ijms241914898.

A multilevel screening pipeline in zebrafish identifies therapeutic drugs for GAN.

Lescouzeres L, Hassen-Khodja C, Baudot A, Bordignon B, Bomont P EMBO Mol Med. 2023; 15(7):e16267.

PMID: 37144692 PMC: 10331585. DOI: 10.15252/emmm.202216267.

Antiepileptic Properties of Scyllo-Inositol on Pentylenetetrazol-Induced Seizures.

Wisniewski K, Antonowski T, Juranek J, Podlasz P, Wojtkiewicz J Int J Mol Sci. 2023; 24(8).

PMID: 37108760 PMC: 10144795. DOI: 10.3390/ijms24087598.

References

Mudher A, Lovestone S . Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci. 2002; 25(1):22-6. DOI: 10.1016/s0166-2236(00)02031-2. View

Yazulla S, Studholme K . Neurochemical anatomy of the zebrafish retina as determined by immunocytochemistry. J Neurocytol. 2002; 30(7):551-92. DOI: 10.1023/a:1016512617484. View

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller H . The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999; 10(3):237-44. DOI: 10.1159/000017126. View

Mount C, Downton C . Alzheimer disease: progress or profit?. Nat Med. 2006; 12(7):780-4. DOI: 10.1038/nm0706-780. View

Cahill G . Clock mechanisms in zebrafish. Cell Tissue Res. 2002; 309(1):27-34. DOI: 10.1007/s00441-002-0570-7. View

Braff D, Geyer M, Swerdlow N . Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001; 156(2-3):234-58. DOI: 10.1007/s002130100810. View

Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E . The ubiquitin pathway in Parkinson's disease. Nature. 1998; 395(6701):451-2. DOI: 10.1038/26652. View

ONeill M, Dix S . AMPA receptor potentiators as cognitive enhancers. IDrugs. 2007; 10(3):185-92. View

Levin E, Limpuangthip J, Rachakonda T, Peterson M . Timing of nicotine effects on learning in zebrafish. Psychopharmacology (Berl). 2005; 184(3-4):547-52. DOI: 10.1007/s00213-005-0162-9. View

10.

Rink E, Wullimann M . Connections of the ventral telencephalon (subpallium) in the zebrafish (Danio rerio). Brain Res. 2004; 1011(2):206-20. DOI: 10.1016/j.brainres.2004.03.027. View

11.

Siuciak J, Chapin D, Harms J, Lebel L, McCarthy S, Chambers L . Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006; 51(2):386-96. DOI: 10.1016/j.neuropharm.2006.04.013. View

12.

Xu X, Scott-Scheiern T, Kempker L, Simons K . Active avoidance conditioning in zebrafish (Danio rerio). Neurobiol Learn Mem. 2006; 87(1):72-7. DOI: 10.1016/j.nlm.2006.06.002. View

13.

Murphey R, Zon L . Small molecule screening in the zebrafish. Methods. 2006; 39(3):255-61. DOI: 10.1016/j.ymeth.2005.09.019. View

14.

Gauthier S, Reisberg B, Zaudig M, Petersen R, Ritchie K, Broich K . Mild cognitive impairment. Lancet. 2006; 367(9518):1262-70. DOI: 10.1016/S0140-6736(06)68542-5. View

15.

Robinson D, Keating G . Memantine: a review of its use in Alzheimer's disease. Drugs. 2006; 66(11):1515-34. DOI: 10.2165/00003495-200666110-00015. View

16.

Hampson R, Rogers G, Lynch G, Deadwyler S . Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci. 1998; 18(7):2740-7. PMC: 6793095. View

17.

Nuechterlein K, Barch D, Gold J, Goldberg T, Green M, Heaton R . Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004; 72(1):29-39. DOI: 10.1016/j.schres.2004.09.007. View

18.

Newman M, Musgrave I, Musgrave F, Lardelli M . Alzheimer disease: amyloidogenesis, the presenilins and animal models. Biochim Biophys Acta. 2007; 1772(3):285-97. DOI: 10.1016/j.bbadis.2006.12.001. View

19.

Wullimann M, Mueller T . Teleostean and mammalian forebrains contrasted: Evidence from genes to behavior. J Comp Neurol. 2004; 475(2):143-62. DOI: 10.1002/cne.20183. View

20.

Galvin J . Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord. 2006; 20(4):302-10. DOI: 10.1097/01.wad.0000213858.27731.f8. View